#ACR 2024 BEST Abstracts from Day 2 Save

Jack Cush, MD

Nov 17, 2024 8:27 pm

Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty.

If high +ANA and NO #rheumatic #disease

LOOK 👀 at #LIVER #Autoimmune #hepatitis
And#alcoholic #liver #dx #ACRBest #ACR24 @rheumnow abst#0627 pic.twitter.com/EVLUyvpBfD
— Janet Pope (@Janetbirdope) November 17, 2024

Bolhuis et al. PMR MODE study. MTX 25mg/week in recently diagnosed PMR. 52 weeks. 56 patients. Nada, zip, no effect. GC free remission 67% vs 68%. No difference in any secondary outcome. @RheumNow #ACR24 Abstr#1697 #ACRbest https://t.co/Mb909u1zFT pic.twitter.com/dShyBF4WST
— Richard Conway (@RichardPAConway) November 17, 2024

Impressive Plenary @andreafava just finished

Novel urine protein panel id 12 proteins that predict NIH activity on renal bx better than existing options

Improving at 3 mos predicts response at 1 year

Could reduce biopsies / modulate tx!#ACR24 @RheumNow Abstr#1642 #ACRbest pic.twitter.com/Gi6u6hAGzj
— Mike Putman (@EBRheum) November 17, 2024

VERY exciting SLE update from Fava et al.

Machine learning used to generate urinary protein panel predictive of intra-renal inflammation

BETTER than serum biomarkers C3, C4, dsDNA

Also monitoring tool for renal response. Outstanding.@RheumNow #ACRbest #ACR24 pic.twitter.com/YXgKrSU4UQ
— Brian Jaros, MD (@Dr_Brian_MD) November 17, 2024

Super helpful results from COVER study, holding JAK or IL17 for COVID boosters

Antibody titers went up regardless of holding

Holding caused flares (14-25% increase!)

Pretty clear message; continue JAK / IL17 #ACR24 @RheumNow Abstr#1718 #ACRbest pic.twitter.com/Mf89dWrRWz
— Mike Putman (@EBRheum) November 17, 2024

Not a basic immuno kinda guy, but really like this graph showing differential effects of available TYK/JAKs

New TYK2i "zasocitinib" remarkably selective for TYK w/no clear JAK 1/3 activity

Could be an interesting option?#ACR24 @RheumNow Abstr#0877 #ACRBest pic.twitter.com/5RLTxIEcpO
— Mike Putman (@EBRheum) November 17, 2024

Quaack etlal. PreCARA study (vs PARA, historical control). T2T in RA improves fertility - time to pregnancy 84 days vs 196 days. T2T strategy also led to less NSAIDs and prednisolone. @RheumNow #ACR24 Abstr#1647 #ACRbest https://t.co/vYCCUqpCLo pic.twitter.com/PUHJOxgGbL
— Richard Conway (@RichardPAConway) November 17, 2024

#ACRBest Day 2 https://t.co/8T7O0FaNu1
— Akhil Sood MD (@AkhilSoodMD) November 17, 2024

#Upadacitinib rises ‘ Up’ in all subgroups of #GCA

Subset of overall #RCT of #rinvoq w more reduction of #steroids vs placebo+ slower #prednisone taper

Consistent results
best in UPA 15 mg >UPA 7.5mg/d > #placebo #ACR24 #ACRBest @RheumNow @ACRheum abst#1695 pic.twitter.com/dA7RkNmWFd
— Janet Pope (@Janetbirdope) November 17, 2024

@kekuchinad A#1689
PFT ref equations -> inequities in SSc ILD

Predict FVC uses age, ht, sex & race
- higher % pred values -> underdx

Race-specific v neutral equations:
More black pts meet trial eligibility (69/57%), immunos (56/40), lung t, (14/9)@RheumNow #ACR24 #ACRBest pic.twitter.com/40PFmdk3Xv
— Eric Dein (@ericdeinmd) November 17, 2024